BioSpace News Archive

XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy

XNK Therapeutics AB announced plans to further expand the scope of its proprietary technology platform of natural killer cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline.

September 29, 2021
·
1 min read
MiZ Company Limited Publishes Review Article on Discovery of Diatomic Molecule That Overcomes Diseases Caused by Chronic Inflammation, Incurable by Modern Medicine

A paper titled “The overlooked benefits of hydrogen-producing bacteria. -Super beneficial Bacteria-,” submitted by MiZ Company Limited and co-authored by the University of California, Berkeley, and Keio University, was accepted in Medical Gas Research on August 30, 2021.

September 29, 2021
·
6 min read
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented three-year results from the TANGO study at IDWeek 2021, being held virtually 29 September - 3 October.

September 29, 2021
·
13 min read
ePharmacy Market | Exclusive Report on the Latest Trends and Opportunities in the Market

The ePharmacy market is growing at a rapid pace on the back of a growing number of technology-savvy consumers, improving digitization in healthcare services, and increasing penetration of internet connectivity at the global platform.

September 29, 2021
·
4 min read
Dental Lasers Demand to Primarily Centralize in North America, Exceeding US$ 250 Mn by 2022

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global dental lasers market is registered year on year growth at 9.0% in 2019.

September 29, 2021
·
7 min read
Policy

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections

Everest Medicines Limited announced the submission of a New Drug Application to the Department of Health, the Hong Kong Special Administrative Region, China, for Xerava™ for the treatment of complicated intra-abdominal infections in adult patients in Hong Kong.

September 29, 2021
·
3 min read
FDA

TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation

TransMedics Group, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Liver System for use with organs from donors after brain death (DBD) and after circulatory death (DCD).

September 29, 2021
·
5 min read
Business

Neurolens Names Mark Kremer Chief Revenue Officer

Following his announcement as CEO, Pierre Bertrand has simplified the leadership structure of Neurolens to ensure unified focus on maintaining the rapid growth trajectory of the organization.

September 29, 2021
·
2 min read
Genetown

Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases

Expansion Therapeutics, Inc today announced the close of an $80 million Series B financing.

September 29, 2021
·
4 min read
Biotech Bay

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., today announced that Health Canada has approved TRUSELTIQ™ (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor (FGFR.

September 29, 2021
·
12 min read